Gennex Lab.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE509C01026
  • NSEID:
  • BSEID: 531739
INR
13.50
0.01 (0.07%)
BSENSE

Dec 05

BSE+NSE Vol: 1.54 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Net Sales
137.90
91.62
69.55
62.59
59.65
55.62
56.58
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
137.90
91.62
69.55
62.59
59.65
55.62
56.58
Raw Material Cost
100.59
57.88
46.91
40.01
34.19
35.13
34.68
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.41
(Increase) / Decrease In Stocks
-3.51
-9.03
-7.00
-1.91
1.53
-1.51
-2.39
Employee Cost
8.35
7.79
7.87
6.97
7.21
6.81
6.12
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
15.76
13.04
13.13
10.76
10.19
11.94
12.96
Total Expenditure (Excl Depreciation)
121.19
69.68
60.91
55.83
53.12
52.37
51.78
Operating Profit (PBDIT) excl Other Income
16.71
21.94
8.64
6.76
6.53
3.25
4.80
Other Income
10.43
0.00
0.00
0.00
0.52
0.95
0.00
Operating Profit (PBDIT)
27.14
21.94
8.64
6.76
7.05
4.20
4.80
Interest
3.61
3.08
1.35
0.88
0.74
0.75
0.98
Exceptional Items
-0.15
0.00
0.00
0.00
-0.37
0.11
0.00
Gross Profit (PBDT)
23.38
18.86
7.29
5.88
5.94
3.56
3.82
Depreciation
1.99
2.37
0.92
0.79
0.88
1.01
0.79
Profit Before Tax
21.40
16.49
6.37
5.09
5.06
2.55
3.03
Tax
3.27
3.32
1.45
1.17
1.02
0.69
0.81
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
18.12
13.18
4.92
3.92
4.04
1.86
2.22
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
18.12
13.18
4.92
3.92
4.04
1.86
2.22
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
-0.08
Minority Interest
-2.00
-0.85
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
16.12
12.32
4.92
3.92
4.04
1.86
2.14
Equity Capital
22.74
22.74
17.66
12.65
12.65
12.65
12.65
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
158.22
141.92
62.33
31.17
27.06
0.00
0.00
Earnings per share (EPS)
0.71
0.54
0.28
0.31
0.32
0.15
0.17
Diluted Earnings per share
0.8
0.61
0.35
0.32
0.32
0.15
0.16
Operating Profit Margin (Excl OI)
12.12%
25.3%
13.17%
11.04%
10.95%
5.84%
8.6%
Gross Profit Margin
16.95%
21.75%
11.11%
9.61%
9.96%
6.4%
6.85%
PAT Margin
13.14%
15.2%
7.5%
6.4%
6.77%
3.34%
3.98%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 50.51% vs 31.73% in Mar 2024

stock-summary

Consolidate Net Profit

YoY Growth in year ended Mar 2025 is 30.84% vs 150.41% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is -23.84% vs 153.94% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 17.21% vs 128.15% in Mar 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2025 has fallen from Mar 2024

Compare Annual Results Of Gennex Lab. With
Markets Mojo
Figures in Cr
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
137.90
379.03
-241.13
-63.62%
Other Operating Income
0.00
0.00
0.00
Total Operating income
137.90
379.03
-241.13
-63.62%
Raw Material Cost
100.59
155.00
-54.41
-35.10%
Purchase of Finished goods
0.00
11.58
-11.58
-100.00%
(Increase) / Decrease In Stocks
-3.51
1.27
-4.78
-376.38%
Employee Cost
8.35
60.76
-52.41
-86.26%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
15.76
106.70
-90.94
-85.23%
Total Expenditure (Excl Depreciation)
121.19
335.31
-214.12
-63.86%
Operating Profit (PBDIT) excl Other Income
16.71
43.72
-27.01
-61.78%
Other Income
10.43
5.78
4.65
80.45%
Operating Profit (PBDIT)
27.14
49.50
-22.36
-45.17%
Interest
3.61
11.39
-7.78
-68.31%
Exceptional Items
-0.15
0.00
-0.15
Gross Profit (PBDT)
23.38
38.11
-14.73
-38.65%
Depreciation
1.99
20.11
-18.12
-90.10%
Profit Before Tax
21.40
18.01
3.39
18.82%
Tax
3.27
5.84
-2.57
-44.01%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
18.12
12.17
5.95
48.89%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
18.12
12.17
5.95
48.89%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
-2.00
0.00
-2.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
16.12
12.17
3.95
32.46%
Equity Capital
22.74
48.73
-25.99
-53.33%
Face Value
1.00
10.00
0.00
Reserves
158.22
203.51
-45.29
-22.25%
Earnings per share (EPS)
0.71
2.50
-1.79
-71.60%
Diluted Earnings per share
0.80
2.50
-1.70
-68.00%
Operating Profit Margin (Excl OI)
12.12%
11.53%
0.00
0.59%
Gross Profit Margin
16.95%
10.05%
0.00
6.90%
PAT Margin
13.14%
3.21%
0.00
9.93%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 137.90 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 50.51% vs 31.73% in Mar 2024

Annual - Consolidate Net Profit
Consolidate Net Profit 16.12 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 30.84% vs 150.41% in Mar 2024

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 16.71 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -23.84% vs 153.94% in Mar 2024

Annual - Interest
Interest 3.61 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 17.21% vs 128.15% in Mar 2024

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 12.12%
in Mar 2025

Figures in %
stock-summary

YoY Growth in year ended Mar 2025 has fallen from Mar 2024